Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Morgan Stanley Maintains Overweight on Cabaletta Bio, Lowers Price Target to $25

Author: Benzinga Newsdesk | November 29, 2023 11:02am
Morgan Stanley analyst Michael Ulz maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and lowers the price target from $28 to $25.

Posted In: CABA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist